LYEL

Lyell Immunopharma Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 3/10
  • Value↓ 0/10
Lyell Immunopharma sales and earnings growth
LYEL Growth
Neutral
  • Revenue Y/Y↓ -40.98%
  • EPS Y/Y↑ 38.77%
  • FCF Y/Y↑ 7.58%
Lyell Immunopharma gross and profit margin trends
LYEL Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -762355.60%
  • ROIC 5Y↓ -53.81%
Lyell Immunopharma net debt vs free cash flow
LYEL Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Lyell Immunopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗